Display options
Cite
Kaur J, Mahajan G, Chand K, et al. Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam. J Clin Diagn Res. 2016;10(1):DC05-8doi: 10.7860/JCDR/2016/15264.7041.
Kaur, J., Mahajan, G., Chand, K., Sheevani, & Chopra, S. (2016). Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam. Journal of clinical and diagnostic research : JCDR, 10(1), DC05-8. https://doi.org/10.7860/JCDR/2016/15264.7041
Kaur, Jaspal, et al. "Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam." Journal of clinical and diagnostic research : JCDR vol. 10,1 (2016): DC05-8. doi: https://doi.org/10.7860/JCDR/2016/15264.7041
Kaur J, Mahajan G, Chand K, Sheevani, Chopra S. Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam. J Clin Diagn Res. 2016 Jan;10(1):DC05-8. doi: 10.7860/JCDR/2016/15264.7041. Epub 2016 Jan 01. PMID: 26894064; PMCID: PMC4740591.
Copy Download .nbib Format: NLM
Share it on

J Clin Diagn Res. 2016 Jan;10(1):DC05-8. doi: 10.7860/JCDR/2016/15264.7041. Epub 2016 Jan 01.

Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam.

Journal of clinical and diagnostic research : JCDR

Jaspal Kaur, Gomty Mahajan, Kailash Chand, Sheevani, Shashi Chopra

Affiliations

  1. Associate Professor, Department of Microbiology, Punjab Institute of Medical Sciences , Jalandhar, India .
  2. Professor, Department of Microbiology, Punjab Institute of Medical Sciences , Jalandhar, India .

PMID: 26894064 PMCID: PMC4740591 DOI: 10.7860/JCDR/2016/15264.7041

Abstract

INTRODUCTION: Routine phenotypic methods employing clavulanate and third generation cephalosporins to detect ESBL are not promising for isolates that co-produce an inhibitor-resistant beta lactamase like AmpC.

AIM: Enhancing phenotypic detection of ESBL in AmpC co-producers by using cefepime and tazobactam.

MATERIALS AND METHODS: A total of 245 isolates of Escherichia coli (123), Klebsiella spp. (87), Proteus spp.(20), Enterobacter spp. (9) and Citrobacter spp.(6) obtained over a period of 2 years from January 2013 to December 2014 from urine samples of hospitalized patients were studied. The isolates were simultaneously screened for ESBL and AmpC production. AmpC production was confirmed by modified three -dimensional test (MTDT). ESBL production was confirmed by original double disc synergy test, phenotypic disc confirmatory test (PDCT) and modified double disc synergy test (MDDST) and the results compared.

RESULTS: AmpC production was confirmed in 113 (46.1%) isolates by modified three dimensional test out of 143 screened positive for AmpC. Of the 192 isolates screened positive for ESBL, ESBL production was confirmed in 162 (66.1%). DDST detected ESBLs in only134 (54.7%) while additional 28 (11.4%) ESBL positive isolates were detected by MDDST. PDCT detected total 145(59.2%) ESBL positive isolates, with cefotaxime and cefotaxime + clavulanate detecting 139 (56.7%) and ceftazidime and ceftazidime + clavulanate detecting additional 6 isolates. All the 28 (11.4%) isolates which were additionally detected ESBL producers by MDDST showed positive three dimensional test i.e. AmpC co producers. DDST detected ESBL in none of AmpC positive isolates while PDCT detected ESBL in 11 isolates showing AmpC co-production. In MDDST cefepime was the best cephalosporin in detecting ESBL in presence of AmpC production. It showed synergism with amoxicillin-clavulanate in 11(39.3%) isolates and in 24(85.7%) isolates with piperacillin-tazobactam. Third generation cephalosporins -cefotaxime, ceftazidime and cefpodoxime were not able to detect ESBL in AmpC-co producers.

CONCLUSION: Modification of double disc synergy tests that combine piperacillin-tazobactum with cefepime enhances the possibility of ESBL detection.

Keywords: Laboratory testing methods; Phenotypic methods; Resistance

References

  1. Indian J Pathol Microbiol. 2013 Apr-Jun;56(2):135-8 - PubMed
  2. Indian J Med Microbiol. 2013 Jan-Mar;31(1):53-9 - PubMed
  3. J Infect Dev Ctries. 2009 Nov 21;4(1):24-9 - PubMed
  4. J Clin Microbiol. 2000 Feb;38(2):542-6 - PubMed
  5. Indian J Med Microbiol. 2004 Apr-Jun;22(2):75-80 - PubMed
  6. J Antimicrob Chemother. 2003 Feb;51(2):415-8 - PubMed
  7. Antimicrob Agents Chemother. 1999 Jun;43(6):1393-400 - PubMed
  8. Med J Armed Forces India. 2013 Jan;69(1):4-10 - PubMed
  9. Indian J Med Microbiol. 2008 Jan-Mar;26(1):58-61 - PubMed
  10. BMC Pharmacol Toxicol. 2015 Jun 02;16:14 - PubMed
  11. Braz J Infect Dis. 2014 Jul-Aug;18(4):421-33 - PubMed
  12. J Antimicrob Chemother. 2001 Feb;47(2):207-10 - PubMed
  13. Clin Infect Dis. 2006 Apr 15;42 Suppl 4:S153-63 - PubMed
  14. J Clin Diagn Res. 2013 Jan;7(1):70-3 - PubMed

Publication Types